TBPH — Theravance Biopharma, Inc. Stock Price, Chart & AI Report

Positive Jul 16, 2026 • 10:00 UTC GlobeNewswire Inc. • Na

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

Zymeworks Inc. announced it will report second quarter 2026 financial results on August 6, 2026, but will not host an earnings conference call due to its pending acquisition of Theravance Biopharma. The company plans to provide updates on the combined business following the expected closing of the acquisition.

ZYME TBPH Q2 2026 earnings Theravance Biopharma acquisition biotherapeutics Ziihera YUPELRI COPD treatment

Sentiment note

Being acquired by Zymeworks provides validation of its assets, particularly YUPELRI, and offers shareholders an exit opportunity. The acquisition indicates market confidence in Theravance's approved product and pipeline.

Positive Jun 29, 2026 • 10:00 UTC GlobeNewswire Inc. • Na

Zymeworks to Acquire Theravance Biopharma, Inc.

Zymeworks announced a definitive agreement to acquire Theravance Biopharma for $17 per share ($929 million) to gain YUPELRI®, a nebulized LAMA for COPD treatment. The acquisition is financed through a $350 million non-recourse note from OMERS Life Sciences and Zymeworks' cash, with the deal expected to be accretive to earnings and cash flow. YUPELRI® generated $266.6 million in U.S. net sales in 2025 with 12% growth, positioning Zymeworks to diversify its revenue streams and fund R&D initiatives.

ZYME TBPH acquisition YUPELRI® COPD treatment non-recourse financing cash flow biopharmaceutical

Sentiment note

Shareholders receive $17 per share acquisition price with unanimous board approval. The company's flagship product YUPELRI® continues to show growth (12% YoY in 2025), and the acquisition provides liquidity while maintaining upside through milestone payments and royalties on other assets like TRELEGY ELLIPTA®.

Negative Apr 3, 2026 • 00:48 UTC Benzinga • Schall Law Firm

TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating Theravance Biopharma for potential securities law violations, alleging the company issued false or misleading statements regarding its CYPRESS trial. The company reportedly spent millions on operations while the trial was in enrollment phase, resulting in significant cash burn before the trial ultimately failed.

TBPH fraud investigation securities violation class action lawsuit CYPRESS trial cash burn failed trial misleading statements

Sentiment note

The company is under investigation for potential securities fraud involving false or misleading statements about its CYPRESS trial. The trial failed after the company spent millions in operational expenses during the enrollment phase, indicating poor capital allocation and potential investor deception.

Negative Mar 3, 2026 • 18:19 UTC Benzinga • Vandana Singh

Theravance Biopharma Plummets As Phase 3 Study Falls Short

Theravance Biopharma (NASDAQ: TBPH) shares plummeted 27.05% after its Phase 3 CYPRESS study failed to meet its primary endpoint for ampreloxetine in treating neurogenic orthostatic hypotension. The company is winding down the ampreloxetine program and implementing significant restructuring, cutting 50% of its workforce and reducing operating expenses by 60% to maximize shareholder value.

TBPH Phase 3 trial failure ampreloxetine neurogenic orthostatic hypotension workforce reduction strategic review biotech clinical trial

Sentiment note

The company's pivotal Phase 3 CYPRESS study failed to meet its primary endpoint, leading to program wind-down. Additionally, the company is implementing major restructuring with 50% workforce reduction and 60% operating expense cuts. Despite a Buy rating from analysts with a $20.20 price target, the stock declined 27.05% on the news, reflecting significant negative market reaction to the failed trial and strategic challenges.

Neutral Feb 22, 2026 • 15:08 UTC The Motley Fool • Lawrence Rothman, Cfa

Irenic Dumps Most Papa John's Shares

Irenic Capital Management LP significantly reduced its Papa John's International position by approximately 70%, selling 748,592 shares in Q4 and retaining only 325,108 shares valued at $12.5 million. The stake now represents just 0.8% of the fund's AUM, dropping out of its top five holdings. Papa John's stock has underperformed the market, declining 30.7% over the past year while the S&P 500 gained 16.4%, amid struggling North American same-store sales.

PZZA ITGR SHC TBPH Papa John's International share sale fund divestment underperformance

Sentiment note

Listed as Irenic's third-largest holding ($51.7 million, 3.5% of AUM) but no specific news or context provided in the article regarding this position.

Neutral Jan 19, 2026 • 12:37 UTC GlobeNewswire Inc. • Researchandmarkets.Com

Neurogenic Orthostatic Hypotension (nOH) Global Clinical Trials Market Review 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status

ResearchAndMarkets.com released a comprehensive clinical trials review for Neurogenic Orthostatic Hypotension (nOH), analyzing global trial landscapes across regions, countries, phases, and sponsor types. The report identifies key trial locations, enrollment trends, and competitive dynamics to support strategic investment decisions in the nOH therapeutics market.

TBPH TAK IQV Neurogenic Orthostatic Hypotension clinical trials G7 countries E7 countries trial phases

Sentiment note

Company is listed as a prominent sponsor in nOH clinical trials, indicating active involvement in the therapeutic space, but no specific trial outcomes or developments are mentioned.

Neutral Aug 13, 2025 • 02:13 UTC The Motley Fool • Jesterai

Theravance Sales Jump 83 Percent

Theravance Biopharma reported Q2 2025 revenue of $26.2 million, driven by YUPELRI sales and a significant one-time gain from TRELEGY royalty asset sale. The company continues to focus on respiratory therapies and is advancing its ampreloxetine clinical program.

TBPH VTRS Theravance YUPELRI ampreloxetine respiratory medicine COPD

Sentiment note

Mixed financial performance with revenue growth and one-time gains, but modest underlying demand and continued operational losses

Unknown Jun 26, 2024 • 16:57 UTC Zacks Investment Research • Zacks Equity Research

AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer

Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.

AZN TBPH HRTX ARQT

Unknown Jun 26, 2024 • 15:28 UTC Zacks Investment Research • Zacks Equity Research

Here's Why You May Invest in Theravance (TBPH) Stock Now

Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.

TBPH RAPT ALGS VTRS

Unknown Jun 21, 2024 • 13:55 UTC Zacks Investment Research • Zacks Equity Research

Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know

The mean of analysts' price targets for Theravance Bio (TBPH) points to a 90.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

TBPH

Unknown Jun 12, 2024 • 15:30 UTC Zacks Investment Research • Zacks Equity Research

Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TBPH ZTS

Unknown May 14, 2024 • 16:06 UTC Zacks Investment Research • Zacks Equity Research

Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates

Theravance's (TBPH) first-quarter 2024 earnings beat estimates while revenues meet the same.

TBPH VTRS THRD